Dependence on LOQTORZI
The company has only one approved commercial product, so any launch, safety, or reimbursement setback would materially affect revenue.
- Scope
- Commercial revenue concentration
- Materiality
- high
Coherus Oncology, Inc.
Coherus Oncology, Inc. is a U.S.-based commercial-stage oncology company focused on proprietary immuno-oncology medicines. Its core business is the commercialization of LOQTORZI (toripalimab-tpzi) and the advancement of mid-stage pipeline candidates aimed at overcoming immune resistance in cancer.
−426,4 %
67,2 %
398,4 %
+59,8 %
1.47
1.45
| % | |
|---|---|
| Commercial oncology product | 70% Approved immuno-oncology therapy sold in the United States and supported by partner commercialization in Canada. |
| Clinical-stage pipeline | 20% Mid-stage and early-stage oncology candidates being developed for additional cancer indications and combinations. |
| Licensing and collaboration rights | 10% Exclusive regional rights, options, and milestone/royalty arrangements tied to toripalimab and related assets. |
The company sells primarily into the oncology treatment ecosystem, where prescribing physicians, hospitals, integrated...
- Oncology prescribersprimary
Medical oncologists and treatment centers that prescribe LOQTORZI based on efficacy, safety, and label fit.
- Hospitals and cancer networksprimary
Hospitals, integrated delivery networks, and cancer centers that decide formulary inclusion and treatment pathways.
- Payers and reimbursement gatekeepersprimary
Government and commercial payers that determine coverage and patient access for oncology biologics.
- Strategic partnerssecondary
License and collaboration partners that help commercialize or develop assets in selected territories.
Coherus Oncology primarily operates in the United States and measures its business as one reportable segment centered...
- •United States is the core commercial and operating market
- •Canada is addressed through a licensing/partner model
- •Other countries are served mainly through partners, not direct ops
- •Biomanufacturing is being onshored to the United States
- •U.S. concentration increases exposure to domestic pricing and reimbursement
The company’s strategy is to build LOQTORZI sales in nasopharyngeal carcinoma while expanding into new indications and...
01
Expand LOQTORZI commercializationshort-term
The approved product is the main revenue engine and the base for future indication expansion.
02
Advance pipeline candidatesmedium-term
Pipeline success is needed to diversify revenue and support long-term growth beyond one marketed product.
03
Strengthen manufacturing controlmedium-term
Reducing dependence on third-party CMOs can improve supply security and commercial readiness.
The business is highly dependent on a single approved product and on successful clinical, regulatory, and commercial...
Clinical and regulatory failure of pipeline assets
Casdozokitug, CHS-114, and other candidates are still in development and may never reach approval.
- Scope
- Pipeline development
- Materiality
- high
Competitive pressure in immuno-oncology
LOQTORZI competes with entrenched PD-1/PD-L1 therapies from much larger companies with stronger commercial resources.
- Scope
- Market share and pricing
- Materiality
- high
Payer and pricing pressure
Coverage, formulary placement, and state/federal drug pricing rules can limit access and net pricing.
- Scope
- U.S. reimbursement
- Materiality
- high
Manufacturing and supply chain reliance
The company relies on CMOs for commercial and clinical supply, which can create delays, quality issues, or cost inflation.
- Scope
- Third-party production
- Materiality
- medium
Product sales discounts and allowances
Can materially change reported product revenue and margins
Collaboration royalties and milestones
Affects gross margin and operating cash requirements
Discontinued operations
Can distort trend analysis across years
Fair value measurements
Can introduce earnings volatility unrelated to core operations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
TuHURA Biosciences, Inc./NV
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
: 28/04/2026